Adaptimmune therapeutics plc ( ap ) is a cell therapy program that has been developed for the last five years. we have developed a strategy for the next five years to deliver this strategy. in this article, we present the first clinical milestones in 2021, and we will provide an update on the future for the development of afami-cel. we will also discuss the progress of our afami-cel program and the future for the development of a new targeted therapy.